POLYPEPTIDE GROUP AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.4 CHF | -1.01% |
|
+1.91% | +67.81% |
| Mar. 12 | PolyPeptide Group AG Provides Earnings Guidance for 2024 | CI |
| Mar. 12 | Transcript : PolyPeptide Group AG, 2023 Earnings Call, Mar 12, 2024 |
| Sales 2024 * | 349M 373M 341M | Sales 2025 * | 407M 435M 398M | Capitalization | 992M 1.06B 971M |
|---|---|---|---|---|---|
| Net income 2024 * | -12M -12.84M -11.74M | Net income 2025 * | 14M 14.99M 13.7M | EV / Sales 2024 * | 3.12 x |
| Net Debt 2024 * | 93.91M 101M 91.89M | Net Debt 2025 * | 132M 141M 129M | EV / Sales 2025 * | 2.76 x |
| P/E ratio 2024 * |
-99.8
x | P/E ratio 2025 * |
64.2
x | Employees | 1,273 |
| Yield 2024 * |
-
| Yield 2025 * |
0.15% | Free-Float | 39.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on PolyPeptide Group AG
More press releases
More news
| 1 day | -1.01% | ||
| 1 week | +1.91% | ||
| Current month | -2.97% | ||
| 1 month | +6.99% | ||
| 3 months | +90.66% | ||
| 6 months | +80.37% | ||
| Current year | +67.81% |
1 week
27.95
29.80
1 month
27.0831.14
Current year
14.1131.14
1 year
14.1131.14
3 years
14.11147.40
5 years
14.11147.40
10 years
14.11147.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 23-04-11 | |
| Chief Tech/Sci/R&D Officer | 52 | 11-12-31 | |
Jens Fricke
COO | Chief Operating Officer | 59 | 22-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 20-12-31 | |
Peter Wilden
CHM | Chairman | 67 | 21-03-31 |
Jane Anne Salik
BRD | Director/Board Member | 71 | 05-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +2.35% | - | |
| 0.00% | 26 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 29.4 | -1.01% | 18,164 |
| 24-04-23 | 29.7 | +5.13% | 33,736 |
| 24-04-22 | 28.25 | -2.59% | 32,780 |
| 24-04-19 | 29 | -0.68% | 22,296 |
| 24-04-18 | 29.2 | +1.39% | 18,424 |
Delayed Quote Swiss Exchange, April 24, 2024 at 11:31 am EDT
More quotes
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
30.1
EUR
Average target price
22.24
EUR
Spread / Average Target
-26.13%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +67.81% | 1.08B | |
| +25.61% | 672B | |
| +25.87% | 570B | |
| -5.24% | 360B | |
| +16.49% | 321B | |
| +8.28% | 300B | |
| +7.09% | 217B | |
| -9.12% | 204B | |
| +5.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- PPGN Stock
